Arex Advisor welcomes Delphine Guérin as new Business Development Director

Portrait of Delphine Guérin

Stockholm, Sweden 2 May 2025 Arex Advisor is delighted to announce the recruitment of Delphine Guérin as our new Business Development Director. Delphine brings a strong track record of driving commercial growth and supporting innovation, with proven expertise in building long term client relationships and navigating complex projects. She holds a PhD in Neuroscience from […]

Arex Advisor welcomes Emily Staaf as Senior Market Access Consultant

Portait of Emily Staaf Senior Consultant Market Access at Arex Advisor

Stockholm, Sweden 13 January 2025 Arex Advisor is happy to welcome Emily Staaf, Senior Market Access Consultant, to the team. Emily brings a comprehensive skill set honed through her work on strategic and operational market access projects in both the pharmaceutical and MedTech sectors. Her proficiency spans the Nordic region as well as global markets, equipping […]

Press release: Medical device specialist joins Arex Advisor

Stockholm, Sweden Arex Advisor AB are pleased to welcome medical device specialist Callum Kitson-Parker to the team. Callum brings valuable knowledge in outsourced medical device development and manufacturing projects, as well as extensive experience in quality management, regulatory submissions and product registrations (IVDR/MDR/FDA/PMDA/UKCA). “Callum’s deep and diverse experience in medical device development stands out in […]

Linnea Brodin

Finance Manager

BSc Business and Economics

Linnea is our Finance Manager. She has a BSc in Business and Economics from Södertörns University and has previously worked in the accounts payable department at Huddinge Kommun.

Staffan Thunell

Founding partner

BSc Economics and BA

Staffan has a long background in entrepreneurship within the life science industry. He has 20+ years experience from posit­ions as Founder, Chair­man, CEO and CFO within medical affairs consulting and small pharma. Previously Staffan worked in executive positions in big pharma and specialty pharma companies.